Jonzobot,

Exactly! The hope is that in BETonMACE2, there will be a much greater enrichment of the best responder population (i.e. diabetic w/ CKD), as well as stricter requirement for co-treatment with SGLT2 inhibitor (and possibly DPP4 inhibitors, GLP1-R agonists) that showed apabetalone synergy, as well as refined endpoints (bye bye stroke, hello heart failure) to give us the home run.

BDAZ